Automation And Digitalization: Solutions Within AUTOMA + Healthcare 2022

AUTOMA + Healthcare is held on September, 26-27, 2022, in Zurich, Switzerland, and gathers leaders from hospitals & healthcare providers, pharmaceutical companies, governmental bodies and institutions with the main goal to contribute to further development of ongoing digital health trends. AUTOMA+ Healthcare is organized as a place to present case-studies, exchange experience in digital transformation and network.

The business program of AUTOMA+ 2022 is created to cover the topics of the healthcare industry:

  • Social aspects of digitalization
  • Data capture and usage from self-monitoring technologies
  • Strategies to improve patient centricity for health systems
  • Building trust in digital health tools
  • New patient-centric solutions
  • Smart digital medical devices and smart hospitals

During 2 days of intensive networking, participants get direct access to the whole value chain of the healthcare industry. Among the highlights of the program is Chief Digital Officers opening panel, leaders talks, business and technical sessions, and start-up closing session.

Healthcare Automation and Digitalization Congress is an annual B2B networking event. Among participants are representatives of Oxford University Hospitals NHS Foundation Trust, University Medicine Essen, Sheba City of Health, Mehilainen, Erasmus University Medical Center, Pfizer, GSK, Takeda and others.

Get more information:  https://bit.ly/3uOeFnj

 

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version